Parkwood LLC Buys 52,180 Shares of Danaher Corporation $DHR

Parkwood LLC raised its stake in shares of Danaher Corporation (NYSE:DHR) by 113.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 98,036 shares of the conglomerate’s stock after purchasing an additional 52,180 shares during the period. Danaher accounts for approximately 1.8% of Parkwood LLC’s investment portfolio, making the stock its 16th biggest position. Parkwood LLC’s holdings in Danaher were worth $20,097,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of DHR. Nuveen LLC bought a new position in Danaher during the 1st quarter worth $833,941,000. GAMMA Investing LLC raised its position in Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock worth $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP raised its position in Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock worth $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Invesco Ltd. raised its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock worth $309,558,000 after purchasing an additional 1,107,998 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Robert W. Baird raised their target price on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft decreased their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Barclays reiterated an “overweight” rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, UBS Group decreased their price target on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $246.35.

Danaher Stock Performance

Shares of DHR opened at $200.32 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a 50-day moving average of $201.93 and a 200-day moving average of $199.41. The company has a market cap of $143.44 billion, a PE ratio of 42.62, a P/E/G ratio of 2.78 and a beta of 0.75. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.